Moreadith Randall 4

What Happened

• Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), exercised 6,500 stock options at $0.06 per share on Feb 2, 2026 (cost $390) and immediately sold the 6,500 shares in the open market the same day for a weighted-average price of $3.03 per share, generating gross proceeds of about $19,680. The filing also reports the conversion/disposition of the derivative instrument related to those options.

Key Details

• Transaction date: 2026-02-02 (reported on Form 4 filed 2026-02-03 — timely; Form 4 is due within two business days)
• Actions and codes: M = option exercise/conversion (6,500 shares acquired at $0.06); S = open-market sale (6,500 shares sold at weighted avg $3.03)
• Sale price range: transactions executed between $3.00 and $3.05 per share (footnote says weighted average; holder can provide breakdown on request)
• Proceeds and cost: gross sale proceeds ≈ $19,680; exercise cost $390; approximate net before taxes/fees ≈ $19,290
• Options status: the stock options exercised were fully vested (footnote F2)
• Shares owned after transaction: not specified in the provided excerpt of the filing

Context

• This is an option exercise followed by an immediate sale (a common cashless/covering transaction) rather than a straight open-market purchase; such transactions are routine and do not by themselves indicate future company performance.
• Transaction codes: M = exercised/conversion of derivative; S = sale. No 10b5-1 plan, gift, or tax-withholding detail was provided in the supplied information.